Dan L. Longo, M.D., *Editor*

Necrotizing Soft-Tissue Infections

Dennis L. Stevens, Ph.D., M.D., and Amy E. Bryant, Ph.D.

NECROTIZING FASCIITIS IS A SURGICAL DIAGNOSIS CHARACTERIZED BY friability of the superficial fascia, dishwater-gray exudate, and a notable absence of pus. This and other necrotizing soft-tissue infections have multiple causes, risk factors, anatomical locations, and pathogenic mechanisms, but all such infections result in widespread tissue destruction, which may extend from the epidermis to the deep musculature.

Necrotizing infections can occur after major traumatic injuries, as well as after minor breaches of the skin or mucosa (e.g., tears, abrasions, lacerations, or insect bites), varicella infection, nonpenetrating soft-tissue injuries (e.g., muscle strain or contusion), or routine obstetrical and gynecologic procedures; they can also occur in postsurgical and immunocompromised patients (Table 1). Although necrotizing infections have common clinical features, various entities have been defined, such as progressive bacterial synergistic gangrene, synergistic necrotizing cellulitis, streptococcal gangrene, gas gangrene (clostridial myonecrosis), and nonclostridial anaerobic cellulitis. Subtle differences may distinguish one entity from another, but the clinical approaches to diagnosis and treatment are similar.

In this review, we describe the clinical and laboratory features of necrotizing fasciitis and other necrotizing soft-tissue infections. We also discuss diagnostic pitfalls and recommended treatment approaches, as well as the effect of delays in surgical intervention on mortality. (Details about pathogenic mechanisms are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.)

From the Veterans Affairs Medical Center, Boise, ID; and the University of Washington School of Medicine, Seattle. Address reprint requests to Dr. Bryant at the Veterans Affairs Medical Center, Infectious Diseases Section, 500 W. Fort St. (Mail Stop 151), Boise, ID 83702, or at amy.bryant@va.gov.

EPIDEMIOLOGIC FEATURES AND CAUSES OF NECROTIZING FASCIITIS

TYPES I AND II INFECTIONS

Necrotizing fasciitis types I and II are distinguished largely by whether the cause is polymicrobial (type I) or monomicrobial (type II).[1] The annual incidence of necrotizing fasciitis ranges from 15.5 cases per 100,000 population in Thailand[2] to 0.3 to 5 cases per 100,000 in other regions.[3-5] The relative incidence of type I and type II infections varies considerably. In some studies, type II infections have accounted for 55 to 87% of all cases of necrotizing fasciitis,[6,7] whereas type I infections have been more prevalent, by a factor of approximately 2, in other studies,[8,9] and in some studies, the incidence of the two types of infection has been similar.[10-12]

Necrotizing fasciitis type I is a polymicrobial infection involving aerobic and anaerobic organisms. It is usually seen in the elderly or in those with underlying illnesses. Predisposing factors include diabetic or decubitus ulcers, hemorrhoids, rectal fissures, episiotomies, and colonic or urologic surgery or gynecologic procedures. Type I infection is often associated with gas in the tissue and thus is

2253

Table 1. Factors Conferring a Predisposition to Specific Necrotizing Soft-Tissue Infections.*

Predisposing Factor	Clinical Syndrome	Etiologic Agent
Major penetrating trauma: crush or deeply penetrating wound	Gas gangrene	*Clostridium perfringens, C. histolyticum,* or *C. novyi*
Minor penetrating trauma	NF type II	
Freshwater laceration		*Aeromonas hydrophila*
Saltwater laceration		*Vibrio vulnificus*
Minor nonpenetrating trauma: muscle strain, sprain, or contusion	NF type II or streptococcal myonecrosis	*Streptococcus pyogenes*
Mucosal breach: mucosal tear (rectal, vaginal, urethral); gastrointestinal, genitourinary or gynecologic surgery	NF type I	Mixed aerobic and anaerobic organisms
Skin breach		
Varicella lesions	NF type II or streptococcal myonecrosis	*S. pyogenes*
Insect bites	NF type II or streptococcal myonecrosis	*S. pyogenes*
Injection drugs	Gas gangrene	*C. perfringens, C. histolyticum, C. novyi,* or *C. sordellii*
Immunocompromised state		
Diabetes with peripheral vascular disease	NF type I	Mixed aerobic and anaerobic organisms
Cirrhosis and ingestion of raw oysters	NF type II	*V. vulnificus*
Neutropenia	Gas gangrene	*C. septicum*
In women: pregnancy, childbirth, abortion (spontaneous or medically induced), gynecologic procedures or surgery	NF type II, streptococcal myonecrosis, or clostridial myonecrosis	*S. pyogenes, C. perfringens,* or *C. sordellii*
Occult factors: colonic lesions, including carcinoma	Spontaneous gas gangrene	*C. septicum*

* Gas gangrene is also known as clostridial myonecrosis.

difficult to distinguish from gas gangrene. Nonclostridial anaerobic cellulitis and synergistic necrotizing cellulitis are type I variants. Both occur in patients with diabetes and typically involve the feet, with rapid extension into the leg. Though nonnecrotizing cellulitis is common in patients with diabetes, necrotizing fasciitis should be considered in patients with systemic manifestations of sepsis, such as tachycardia, leukocytosis, acidosis, or marked hyperglycemia.

Bacterial penetration into the fascial compartments of the head and neck may result in Ludwig's angina (i.e., infection of the submandibular fascial spaces) or Lemierre's syndrome (thrombophlebitis of the jugular vein), with or without severe sepsis.[13,14] Breach of the gastrointestinal or urethral mucosa may result in Fournier's gangrene, which begins abruptly with severe pain and may spread rapidly from the perineal region to the anterior abdominal wall, the gluteal muscles, and in males, the genitalia. Finally, an indolent polymicrobial infection known as progressive bacterial synergistic gangrene or large phagedenic ulcer[15] can follow surgery involving colostomy sites or wire sutures. Though large ulcerations often develop, the process does not involve the fascia.

Necrotizing fasciitis type II is a monomicrobial infection (Table 1). Among gram-positive organisms, group A streptococcus remains the most common pathogen,[2,4,7,11,16] followed by methicillin-resistant *Staphylococcus aureus* (MRSA).[17,18] Unlike type I infections, type II infections may occur in any age group and in persons without any underlying illness.

Other pathogens include *Aeromonas hydrophila* and *Vibrio vulnificus.* Some experts have proposed that infections with these microbes, and possibly clostridial species, be classified as necrotizing fasciitis type III. Monomicrobial necrotizing fasciitis due to gram-negative pathogens (bacteroides and *Escherichia coli*) has also been reported,[6,19-21] though these infections are typically seen in immunocompromised, diabetic, obese,

or postoperative patients or in those with preexisting, chronic organ dysfunction and are not typically classified as necrotizing fasciitis type II. Resolution of these nomenclature issues requires a consensus among international infectious disease physicians, surgeons, and intensive care practitioners.

The classic clinical and histologic features of necrotizing group A streptococcal and clostridial infections are mediated by potent bacterial exotoxins and by the host response. For details, see the Supplementary Appendix.

INVASIVE GROUP A STREPTOCOCCAL SOFT-TISSUE INFECTIONS

A 2005 report estimated that more than 18 million people worldwide have invasive *Streptococcus pyogenes* diseases,[22] including postpartum infections.[23] In developed countries, the annual incidence of invasive infections has remained steady at 3 to 5 cases per 100,000 population,[3,24,25] with an average mortality of 29%.[24,26] Mortality is higher among patients in whom streptococcal toxic shock syndrome or septic shock develops (38% and 45%, respectively).[24,25]

Two distinct clinical presentations have been described: infection with a defined portal of bacterial entry and infection that arises spontaneously in the deep tissue, without an overt wound or lesion (Fig. 1). *S. pyogenes* gains entry to the deep tissues through superficial cutaneous lesions (chickenpox vesicles, insect bites, or lacerations), after breaches of skin or mucosal integrity (due to drug injections, surgical incisions, or childbirth), or after penetrating trauma. The initial lesion may appear to be only mildly erythematous, but over a period of 24 to 72 hours, inflammation becomes extensive, the skin turns dusky and then purplish, and bullae appear. Bacteremia is frequently present, and metastatic infections may occur. Very rapidly, the skin becomes frankly gangrenous and undergoes extensive sloughing. The patient is now perilously ill, with a high temperature and extreme prostration. At this stage, mortality is high, even with appropriate treatment.[24,27]

In approximately 50% of patients with group A streptococcal necrotizing fasciitis or myonecrosis, infection initiates deep in the soft tissues, without a portal of entry, often at sites of nonpenetrating trauma (muscle strain or bruise).[26,28,29] Initially, only fever and crescendo pain (rapid

pain escalation sufficiently severe to require ketorolac or narcotics) may be present, and such pain prompts patients to seek urgent medical care. Malaise, myalgias, diarrhea, and anorexia may also be present in the first 24 hours. Since cutaneous manifestations are absent initially, the infection is often misdiagnosed or the correct diagnosis is delayed,[30] and as a result, the mortality exceeds 70%.[28] By the time ecchymoses and bullae develop, tissue destruction is extensive, and systemic toxicity and organ failure are evident. Emergency surgery, including extensive débridement or multiple amputations, is often required to ensure survival and necessitates prolonged hospitalization.[26,30-32] Erroneous diagnoses include severe muscle strain and deep-vein thrombophlebitis; because of the associated gastrointestinal manifestations, food poisoning may also be diagnosed in error. Although seeding of the deep tissues probably occurs through transient bacteremia from the nasopharynx, reports rarely document coexisting or antecedent symptomatic pharyngitis (unpublished data). This might be expected, given the incidence of invasive disease (18 million cases) as compared with pharyngitis (>600 million cases).[22] In children, invasive streptococcal infections have been associated with varicella zoster[33-35] and influenza virus infections,[36] as well as streptococcal pharyngitis,[37] though relatively few cases of necrotizing fasciitis have been reported.

The toxicity of group A streptococcal necrotizing fasciitis is severe and more fulminant than that described by Meleney in 1924.[38] Ecchymoses and bullae develop more rapidly (in 2 to 3 days) and deep-muscle involvement is more common in contemporary cases. The mortality is also higher. Using only "bear claw fasciotomy" and irrigation with Dakin's solution (hypochlorous acid) as treatment, Meleney reported a mortality of 20%, as compared with a mortality of 30 to 80% in the current era.[27] Given the involvement of epidermis, dermis, subcutaneous tissue, fascia, and muscle, "necrotizing soft-tissue infection" appears to be a more accurate term than "necrotizing fasciitis" to describe the contemporary disease.

NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND GROUP A STREPTOCOCCAL INFECTION

In the 1980s, an association between the use of nonsteroidal antiinflammatory drugs (NSAIDs) and the development of group A streptococcal

A Defined Portal of Entry

Dermal papilla

Capillaries

Skin or mucosal breach

EPIDERMIS

Organisms or spores

DERMIS

SUBCUTANEOUS FAT

Blood vessels

MUSCLE   Deep fascia

BONE

Erythema and swelling

Local tissue damage

Exotoxins

Damage to blood supply

Platelet–leukocyte aggregation

Bullae   **Ecchymoses**

Bullae

Large bulla

Vascular occlusion

Necrosis in multiple tissue layers

Damage to deep tissue

Organisms or spores are introduced into soft tissue. Exotoxins are released.

Exotoxins cause local tissue damage. Platelet–leukocyte aggregates occlude capillaries and damage vascular endothelium.

Erythema and swelling become widespread. Bullae and ecchymoses develop.

Deeper tissues become infected. Larger venules and arterioles are occluded. Necrosis affects all tissue layers.

B No Defined Portal of Entry

EPIDERMIS

DERMIS

Activated myogenic progenitors

Leukocytes

Deep fascia

Deep-tissue injury

Vimentin

Myogenic progenitor

Group A streptococci

Streptococci

Platelet–leukocyte aggregation

Venous occlusion

Exotoxins

Ecchymoses

Bulla

Gradual upward progression of infection

Arterial occlusion

A nonpenetrating deep-tissue injury stimulates a repair response. There is an influx of leukocytes and activation of myogenic progenitor cells.

In susceptible hosts with transient bacteremia, organisms are trafficked to injury site in a vimentin-mediated process.

Exotoxins are released. Venous occlusion leads to necrosis in deep tissue.

Arteries become occluded, causing necrosis in deep tissue that spreads to upper tissue layers. Bullae and ecchymoses later develop.

Figure 1 (facing page). Evolution of Necrotizing Fasciitis or Myonecrosis.

Panel A shows the evolution of infections with a defined portal of entry. A breach in the skin or mucosal integrity facilitates the introduction of organisms or spores into soft tissue, resulting in monomicrobial infection (with group A streptococcus, *Aeromonas hydrophila*, or *Vibrio vulnificus*) or polymicrobial infection (with both aerobes and anaerobes). Penetrating trauma sufficient to interrupt the blood supply favors the development of gas gangrene (clostridial myonecrosis). Bacteria proliferate and release exotoxins, which cause local tissue damage and impair inflammatory responses. Toxin-induced platelet–leukocyte aggregates occlude capillaries and damage the vascular endothelium, resulting in fluid leakage, tissue swelling, and erythema. Erythema and swelling become more widespread, bullae and ecchymoses develop, and deeper tissues become infected. Exotoxin production leads to occlusion of larger venules and arterioles, with subsequent ischemic necrosis of all tissue layers, from the dermis to the deep musculature. Panel B shows the evolution of group A streptococcal infection with no defined portal of entry (cryptogenic infection). A deep, nonpenetrating tissue injury such as muscle strain, sprain, or hematoma stimulates a repair response, including an influx of leukocytes and activation and proliferation of myogenic progenitor cells. In a susceptible host with a transient bacteremia (possibly arising from asymptomatic pharyngeal carriage of *Streptococcus pyogenes*), the injury leads to trafficking of the organisms to the injured site. Increased vimentin expression on activated myogenic progenitor cells and infiltrated macrophages serves as a ligand for group A streptococcus binding. Bacterial proliferation with local production of exotoxins (e.g., streptolysin O and streptococcal pyrogenic exotoxin A) ensues. Absorption of streptolysin O may stimulate intravascular accumulation of platelet–leukocyte aggregates, first in postcapillary venules and then in arterioles and larger vessels, resulting in vascular occlusion. Ischemic destruction of the deep soft tissues ensues. Cutaneous manifestations of necrotizing infection (ecchymoses and bullae) develop later in the course of infection.

necrotizing fasciitis was proposed. Proponents recognized that NSAIDs can suppress critical neutrophil functions[39] and augment the production of tumor necrosis factor α, a key mediator of septic shock.[39] Other people argued that NSAIDs merely mask the signs and symptoms of developing infection, delaying diagnosis and treatment. Numerous clinical and epidemiologic studies have investigated, but not resolved, this issue.[40-46] Experimental evidence is limited, though two studies clearly showed that nonselective NSAIDs (e.g., ketorolac and ibuprofen) accelerated the disease course and worsened outcomes.[47,48] In addition, ketorolac significantly

increased trafficking of circulating group A streptococci to strain-injured muscles in mice.[49]

NECROTIZING CLOSTRIDIAL INFECTIONS

Gas gangrene (clostridial myonecrosis) is an acute invasion of healthy living tissue that occurs spontaneously or as a result of traumatic injury. Recurrent gas gangrene, occurring several decades after the primary infection, has also been described.[50]

Deeply penetrating injuries that compromise the blood supply create an anaerobic environment that is ideal for spore germination and bacterial proliferation.[51] Such trauma accounts for approximately 70% of cases of gas gangrene. Other predisposing conditions are bowel and biliary tract surgery, intramuscular epinephrine injection, retained placenta, prolonged rupture of the membranes, and intrauterine fetal death. *Clostridium perfringens* causes approximately 80% of such infections; other pathogens include *C. septicum*, *C. novyi*, and *C. histolyticum*.

Data regarding contamination versus active infection of traumatic wounds come from studies performed during World Wars I and II. In 1915, Fleming documented that 60.4% of war wounds were contaminated with clostridia.[52] Yet MacLennan[53] found that active infection (gas gangrene or "anaerobic cellulitis") occurred in fewer than 10 patients per 1000 wounded.[54] In 1941, Qvist[55] suggested that anaerobic cellulitis required only débridement of tissue that was damaged by trauma itself, whereas in gas gangrene, amputation was necessary to control rapid invasion of healthy tissue and thus ensure survival — a premise that guides clinical practice today.

Spontaneous (nontraumatic) gas gangrene is commonly caused by *C. septicum*, which is more aerotolerant than other clostridial pathogens.[56] Most infections occur in patients with gastrointestinal portals of entry such as adenocarcinoma[56] or in those with congenital or cyclic neutropenia.[57] *C. sordellii* infections can affect women after natural childbirth, as well as after abortion or other gynecologic procedures. Such infections can also develop in men, women, and children after traumatic injuries and surgical procedures or illicit-drug injection.[58] Common sites include the skin, muscle, uterus, and perineum. Systemic signs include an absence of fever, profound hypotension, diffuse capillary leak, hemoconcentration

Table 2. Pitfalls in the Diagnosis of Necrotizing Soft-Tissue Infection.*	
Pitfall	Explanation
Absence of fever	Fever is often absent in patients with necrotizing soft-tissue infections because of NSAIDs that are self-administered or prescribed in the emergency department or in postsurgical settings. Fever is also absent in patients with necrotizing infection due to *C. sordellii*.
Absence of cutaneous manifestations	Patients with spontaneous or cryptogenic necrotizing infections (i.e., infections without an obvious bacterial portal of entry) that begin in the deep soft tissues often do not have cutaneous signs of infection until late in the course of the disease.
Attributing severe pain to injury or procedure	Severe pain is a key finding in patients with necrotizing infections. However, when such infections develop after surgery or parturition, pain may be erroneously attributed to the procedure itself. Similarly, perineal pain may be attributed to hemorrhoids, epididymitis, or vaginal or rectal trauma. Severe pain associated with spontaneous or cryptogenic infections is often wrongly attributed to muscle strain or venous thrombosis. If pain is out of proportion to the suspected cause or requires opioids or ketorolac for management, a developing necrotizing infection should be considered. Pain may be absent because of the use of narcotics or NSAIDs or because of neuropathy in patients with diabetes.
Nonspecific imaging tests	In patients with necrotizing infections, radiographs may show only edema, with no evidence of gas in the deep tissue. Since this finding is consistent with noninfectious causes (e.g., soft-tissue injury and postsurgical and postpartum conditions), it may confound the diagnosis.
Attributing systemic manifestations to other causes	Nausea, vomiting, and diarrhea may be early manifestations of toxemia from group A streptococcal infection, though they are often wrongly attributed to food poisoning or viral illness.

* NSAIDs denotes nonsteroidal antiinflammatory drugs.

(hematocrit, 50 to 80%), and a marked leukemoid reaction (white-cell count, 50,000 to 150,000 per cubic millimeter). Mortality is 70 to 100%, and death occurs within 2 to 4 days after hospital admission.

DIAGNOSIS OF NECROTIZING FASCIITIS AND OTHER NECROTIZING INFECTIONS

DIAGNOSTIC PITFALLS

Early diagnosis of necrotizing infections may be confounded by numerous factors (Table 2), as discussed below. Physicians must be aware of these potential pitfalls because delays in diagnosis and treatment have dire consequences. A basic diagnostic algorithm is shown in Figure 2.

CLINICAL FINDINGS

Classic manifestations of necrotizing fasciitis include soft-tissue edema (in 75% of cases), erythema (72%), severe pain (72%), tenderness (68%), fever (60%), and skin bullae or necrosis (38%).[8] In a recent case–control study, factors that differentiated necrotizing fasciitis from cellulitis were recent surgery, pain out of proportion to clinical signs, hypotension, skin necrosis, and hemorrhagic bullae.[59]

In patients with cryptogenic group A streptococcal infection (i.e., infection with no portal of entry), the process begins deep in the tissues. Crescendo pain is the most important clinical clue for such infection, and its onset typically occurs well before shock or organ dysfunction is manifested. However, crescendo pain may be absent or attenuated in patients who are receiving analgesic agents, including NSAIDS; in patients who have undergone surgery, childbirth, or trauma, the pain may be incorrectly attributed to normal postoperative soreness, typical postpartum discomfort, or the trauma itself, respectively, rather than to acute infection. Pain may also be absent in patients with altered mental status or those with diabetes-related neuropathy. In these instances, the absence of a strong clinical clue delays the correct diagnosis and appropriate treatments. Thus, all patients presenting with a sudden onset of severe pain in an extremity, with or without an obvious portal of bacterial entry or the presence of fever, should be evaluated for severe soft-tissue infection on an emergency basis.

IMAGING TESTS

Radiographs, computed tomographic (CT) scans, or magnetic resonance imaging (MRI) studies will show soft-tissue swelling in patients with group A streptococcal infection and will show

Clinical Symptoms

Swelling, erythema, pain

Systemic Signs

Tachycardia, >120 beats/min; hypotension; elevated CK level; CRP, >15 mg/dl; LRINEC score, >6

No systemic signs

Radiographic Evidence

Gas in the tissue

No gas in the tissue

Immediate Surgery

Inspection and débridement Specimen collection

Inspection and débridement Specimen collection

Gram's Staining and Culture

Gram-positive rods

Mixed aerobes and anaerobes

Gram-positive cocci

Gram-negative rods

Differential Diagnosis

Clostridial myonecrosis (aggressive)
Spontaneous —
Clostridium septicum
Traumatic —
C. perfringens
Gynecologic —
C. sordellii
Clostridial anaerobic cellulitis (indolent)

NF Type I
Nonclostridial crepitant cellulitis
Synergistic necrotizing cellulitis
Progressive bacterial synergistic gangrene

NF Type II
Streptococcus pyogenes
Staphylococcus aureus
or group A streptococcal myonecrosis

NF Type II
Aeromonas
Freshwater
Vibrio
Saltwater

Cellulitis
Erysipelas
Cutaneous abscess

Figure 2. Algorithm for the Diagnosis of Necrotizing Infections.

In the algorithm, early clinical signs and symptoms and available results of laboratory tests and imaging studies are used to establish the diagnosis and cause of a diverse array of skin and soft-tissue infections. CK denotes creatine kinase, CRP C-reactive protein, LRINEC Laboratory Risk Indicator for Necrotizing Fasciitis, and NF necrotizing fasciitis.

gas in the tissues of patients with gas gangrene or necrotizing fasciitis type I. Imaging evidence of gas in the tissues, or the presence of crepitus, should prompt immediate surgical consultation. A finding of swelling alone may not be useful in patients who have had a traumatic injury or have undergone surgery or childbirth, since swelling cannot be used to distinguish between infection, trauma, and inflammation. MRI may show thickening and hyperintensity of intermuscular fascia on T$_2$-weighted images, findings that are sensitive but not entirely specific for necrotizing fasciitis.

A study of enhanced CT in patients with documented necrotizing fasciitis as compared with those who had other musculoskeletal infections suggested that the absence of fascial enhancement was specific for necrotizing fasciitis.[60]

TISSUE BIOPSY, HISTOLOGIC TESTS, AND GRAM'S STAINING

Gram's staining of surgically obtained material is crucial for determining the cause of infection and guiding empirical treatment. Percutaneous biopsy and examination of a frozen section has

been proposed to aid in the diagnosis of necrotizing infection.[61,62] However, this technique is subject to sampling error and is not a good substitute for open surgical inspection and biopsy. Group A streptococcal necrotizing infection is characterized histologically by the destruction of muscle tissue, a paucity of infiltrating phagocytes, and large numbers of gram-positive cocci at the site (Fig. 3). The histologic findings are similar for gas gangrene, though with more evidence of edema, gas formation, or both.

SURROGATE MARKERS FOR EARLY DIAGNOSIS OF NECROTIZING FASCIITIS

A C-reactive protein level of more than 200 mg per liter,[63] a modestly increased white-cell count with a marked left shift,[64] and an elevated serum creatinine level in the absence of hypotension are suggestive of severe group A streptococcal infection. Marked leukemoid reactions (50 to 150,000 white cells per cubic millimeter) and profound hemoconcentration are characteristic of *C. sordellii* infection. A white-cell count of more than 15,400 per cubic millimeter plus a serum sodium level of less than 135 mmol per liter distinguishes necrotizing fasciitis in general from nonnecrotizing soft-tissue infections, with a negative predictive value of 99% but a positive predictive value of only 26%.[64] Elevated levels of serum creatine phosphokinase or serum aspartate aminotransferase suggest deep infection involving muscle or fascia (as opposed to cellulitis).

The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) scoring system uses the total white-cell count and hemoglobin, sodium, glucose, creatinine, and C-reactive protein levels to distinguish between mild soft-tissue infections and necrotizing fasciitis.[65,66] For adults with LRINEC scores of 5.8 or higher (on a scale of 0 to 13, with higher scores indicating a greater likelihood of necrotizing soft-tissue infection), the positive predictive value for necrotizing fasciitis ranged from 57 to 92% in three studies,[4,65,67] with negative predictive values of 86% and 96% in two studies.[65,68] The disparities may be attributable, in part, to the fact that the specificity of the LRINEC score is greatest for severe disease.[9] In a study involving children with necrotizing fasciitis, the median LRINEC score was only 3.7.[69]

TREATMENT

SURGICAL INTERVENTION

For patients with aggressive soft-tissue infection or those with mild infection plus evidence of systemic toxicity, prompt surgical exploration is extremely important[8,32,70] for three reasons: to determine the extent of infection, to assess the need for débridement or amputation, and to obtain specimens for Gram's staining and culture. When infection is near the vital structures of the neck, surgical intervention may be necessary to prevent airway obstruction. Reinspection of the surgical site within 24 hours after surgery is recommended.[8,70] Inspection and débridement should be continued every 1 to 2 days until necrotic tissue is no longer present.[8,32,62,70-72] Negative-pressure devices have shown promise in facilitating closure and healing of these complex wounds in small series of patients.[73-75]

There is universal agreement that early surgical débridement is crucial in managing these complex cases. But how early is early? Pinpointing the critical time for surgical intervention on the basis of published data is problematic, since the starting point for measuring the time to surgery varies among studies, particularly retrospective analyses, with some studies using the time from establishment of a definitive diagno-

Figure 3. Histopathological Features of Group A Streptococcal Necrotizing Fasciitis and Myonecrosis.

Routine hematoxylin and eosin staining of a muscle specimen from a patient who died from cryptogenic group A streptococcal infection shows the classic features of this infection: widespread tissue destruction, lack of a tissue inflammatory response, and large numbers of bacteria in the tissues.

sis, some using the time from initial recognition of the infection, and others using the time from hospital admission. Studies at tertiary care hospitals typically report the shortest times to surgery, probably because the diagnosis was made elsewhere, before admission to the study hospital. We agree with Bandyopadhyay and colleagues[71] that the definition of the time to surgery should be standardized.

Nevertheless, survival is significantly increased among patients taken to surgery within 24 hours after admission as compared with those in whom surgery is delayed for more than 24 hours.[8,76] Survival is further increased with earlier surgical intervention (e.g., within 6 hours),[77,78] supporting the notion that the earlier surgery is performed, the better the outcome.

PHARMACOLOGIC TREATMENT

Polymicrobial Necrotizing Infections
For mixed aerobic and anaerobic infections of the head and neck, abdomen, perineum, or gynecologic organs, definitive treatment should be based on Gram's staining, culture, and sensitivity information. Because of antibiotic resistance in gram-positive microbes and among the Enterobacteriaceae,[79] broader antibiotic coverage may be necessary, particularly if the patient has recently been hospitalized or treated with antibiotics. Treatment should also be guided by local antibiograms, since the emergence of resistance is geographically determined and specific.[80] The Infectious Diseases Society of America (IDSA) publishes guidelines for the treatment of skin and soft-tissue infections.[70] The current guidelines recommend vancomycin or linezolid plus one of the following therapies: piperacillin–tazobactam, a carbapenem, or ceftriaxone–metronidazole. Additional information on specific and alternative treatments is also provided in the IDSA guidelines. Studies are under way to evaluate ceftazidime–avibactam for highly resistant gram-negative microbes.[81]

Group A Streptococcal Infections
Treatment with clindamycin in combination with penicillin for 10 to 14 days is recommended for group A streptococcal infection.[70] Clindamycin monotherapy should be considered only after antibiotic susceptibility has been determined, since both constitutive and inducible resistance

in group A streptococcus have increased, to 15% in the United States[82] and to 95.5% in China.[83] Treatment failures have been reported in cases of clindamycin resistance.[84] In a study of experimental myonecrosis due to group A streptococcus with resistance to erythromycin and clindamycin, tedizolid, a second-generation oxazolidinone antibiotic, was highly efficacious and superior to linezolid.[85]

Other Necrotizing Fasciitis Type II Infections
Current guidelines recommend that *A. hydrophila* infections be treated with doxycycline plus either ciprofloxacin or ceftriaxone.[70] A combination of doxycycline plus either ceftriaxone or cefotaxime is recommended for *V. vulnificus* infections.[70] For MRSA infections, vancomycin, linezolid, daptomycin, or ceftaroline is likely to be effective, though such treatment has not been adequately studied.

Traumatic or Spontaneous Gas Gangrene
Treatment with penicillin plus clindamycin for 10 to 14 days is recommended for traumatic or spontaneous gas gangrene.[70] The recommendation of penicillin is based on in vitro sensitivity data. The recommendation of clindamycin is based on data showing that it is more effective than penicillin in animal models of gas gangrene caused by *C. perfringens*[86]; clinical trials of clindamycin have not been performed.

CARE OF CRITICALLY ILL PATIENTS

Guidelines for the care of critically ill patients have recently been published.[87] However, problems specifically associated with necrotizing infections are of concern, as noted below.

Capillary Leak Syndrome
Circulating bacterial toxins and host mediators cause diffuse endothelial damage. Intravenous fluid requirements may be extremely high (10 to 12 liters of normal saline per day). However, profound hypoalbuminemia (0.5 to 1 g per deciliter) is also common, and replacement with colloid (albumin) may therefore be necessary to maintain oncostatic pressure.

Intravascular Hemolysis
Bacterial hemolysins cause striking and rapid reductions in the hematocrit in the absence of

disseminated intravascular coagulopathy. Thus, the hematocrit may be a better indicator of the need for transfusion than the hemoglobin level.

Cardiomyopathy

Global hypokinesia, as indicated by echocardiography and cardiac output, is seen in some patients with streptococcal toxic shock syndrome.[88] Among survivors, this cardiomyopathy is reversible, fully resolving in 3 to 24 months after infection. Some patients have survived with the use of cardiac-assist devices. Management is difficult, since use of vasopressors increases afterload, resulting in decreased peripheral perfusion and reduced cardiac output. Symmetric gangrene resulting in loss of one to four extremities has been described. Careful monitoring and maintenance of mean arterial pressure so that it does not exceed 65 mm Hg in patients with this infection seem prudent, though no clinical studies have been performed to support this recommendation.

ADJUNCTIVE MEASURES

Hyperbaric Oxygen

A review of 57 studies performed between 1997 and 2003 concluded that hyperbaric oxygen is not useful for the treatment of necrotizing fasciitis,[89] a finding that is similar to the results of other studies.[8,90,91] In contrast, a significant survival benefit of hyperbaric oxygen in necrotizing fasciitis was documented in recent studies from the United States and Australia.[11,92] Other studies have also suggested a beneficial role of hyperbaric oxygen in the treatment of gas gangrene,[89,91] though experimental studies showed no benefit.[93] Recently, a study has been initiated to evaluate the effect of hyperbaric oxygen on inflammatory and vasoactive biomarkers in necrotizing infections.[94] Meanwhile, its benefits remain controversial. Surgical débridement, which is essential for the treatment of necrotizing fasciitis, should not be delayed in order to pursue hyperbaric oxygen treatment.

Intravenous Immune Globulin

The rationale for using intravenous immune globulin (IVIG) in patients with necrotizing fasciitis is based on its ability to neutralize extracellular toxins that mediate pathogenesis. Clinical studies suggesting that there are benefits to IVIG have had serious limitations, including differences in surgical intervention or clindamycin use between the group that received IVIG and the group that did not,[95] lack of power due to the small sample size,[96] low mortality in the group that did not receive IVIG,[97] and differences in the incidence of necrotizing fasciitis between the two study groups.[98] Furthermore, both the quantity and quality of neutralizing antitoxin antibodies vary from batch to batch of IVIG. In view of these limitations and the lack of data from definitive double-blind, controlled studies, the IDSA does not recommend IVIG for necrotizing group A streptococcal infections.[70] Other investigators are in agreement.[72] In a well-controlled 2017 study involving 4127 patients with necrotizing fasciitis and streptococcal toxic shock syndrome in 130 hospitals in the United States, IVIG had no effect on mortality or length of hospital stay.[99] Thus, though IVIG has its advocates, a consensus supporting its use has not been reached.

Other Measures

A phase 2 trial of a new inhibitor of bacterial superantigens showed no significant benefit with respect to survival, number of surgical débridements, or serum cytokine levels.[100]

SUMMARY

Necrotizing soft-tissue infections share many clinical and pathological features, and all such infections result in extensive tissue destruction. No single clinical laboratory test or group of tests can adequately replace surgical inspection for diagnosis of these infections. Early diagnosis, prompt surgical intervention, and appropriate antibiotic treatment are essential to reduce mortality and improve outcomes.

REFERENCES

1. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2015:1194-215.

2. Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Tantraworasin A. Necrotizing fasciitis: epidemiology and clinical predictors for amputation. Int J Gen Med 2015;8:195-202.

3. Naseer U, Steinbakk M, Blystad H, Caugant DA. Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2016;35:1639-48.

4. Glass GE, Sheil F, Ruston JC, Butler PE. Necrotising soft tissue infection in a UK metropolitan population. Ann R Coll Surg Engl 2015;97:46-51.

5. Bocking N, Matsumoto CL, Loewen K, et al. High incidence of invasive group A streptococcal infections in remote indigenous communities in northwestern Ontario, Canada. Open Forum Infect Dis 2016;4(1):ofw243.

6. Jabbour G, El-Menyar A, Peralta R, et al. Pattern and predictors of mortality in necrotizing fasciitis patients in a single tertiary hospital. World J Emerg Surg 2016;11:40.

7. Nordqvist G, Walldén A, Brorson H, Tham J. Ten years of treating necrotizing fasciitis. Infect Dis (Lond) 2015;47:319-25.

8. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-63.

9. van Stigt SF, de Vries J, Bijker JB, et al. Review of 58 patients with necrotizing fasciitis in the Netherlands. World J Emerg Surg 2016;11:21.

10. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003;85-A:1454-60.

11. Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotising soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care 2015;43:685-92.

12. Kulasegaran S, Cribb B, Vandal AC, McBride S, Holland D, MacCormick AD. Necrotizing fasciitis: 11-year retrospective case review in South Auckland. ANZ J Surg 2016;86:826-30.

13. Suzuki K, Hayashi Y, Otsuka H, et al. Case report: a case of Lemierre's syndrome associated with necrotizing fasci-itis and septic embolization. Nihon Naika Gakkai Zasshi 2016;105:99-104. (In Japanese.)

14. Tawa A, Larmet R, Malledant Y, Seguin P. Severe sepsis associated with Lemierre's syndrome: a rare but life-threatening disease. Case Rep Crit Care 2016;2016:1264283.

15. Luckett WH. VII. Large phagedenic ulcer of the abdomen. Ann Surg 1909;50:605-8.

16. Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003-2013. Epidemiol Infect 2016;144:1338-44.

17. Cheng NC, Wang JT, Chang SC, Tai HC, Tang YB. Necrotizing fasciitis caused by *Staphylococcus aureus*: the emergence of methicillin-resistant strains. Ann Plast Surg 2011;67:632-6.

18. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant *Staphylococcus aureus* in Los Angeles. N Engl J Med 2005;352:1445-53.

19. Tsai YH, Shen SH, Yang TY, Chen PH, Huang KC, Lee MS. Monomicrobial necrotizing fasciitis caused by *Aeromonas hydrophila* and *Klebsiella pneumoniae*. Med Princ Pract 2015;24:416-23.

20. Yahav D, Duskin-Bitan H, Eliakim-Raz N, et al. Monomicrobial necrotizing fasciitis in a single center: the emergence of Gram-negative bacteria as a common pathogen. Int J Infect Dis 2014;28:13-6.

21. Lee CY, Kuo LT, Peng KT, Hsu WH, Huang TW, Chou YC. Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens. BMC Infect Dis 2011;11:5.

22. Sims SA, Colquhoun S, Wyber R, Carapetis JR. Global disease burden of group A streptococcus. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. *Streptococcus pyogenes*: basic biology to clinical manifestations. Oklahoma City: University of Oklahoma Health Sciences Center, 2016:19785-8.

23. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis 2013;57:870-6.

24. Nelson GE, Pondo T, Toews KA, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Clin Infect Dis 2016;63:478-86.

25. Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive *Streptococcus pyogenes* infections in France in 2007. J Clin Microbiol 2011;49:4094-100.

26. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infec-tions associated with a toxic shock–like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.

27. Wong CJ, Stevens DL. Serious group A streptococcal infections. Med Clin North Am 2013;97:721-736, xi-xii.

28. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985;145:1020-3.

29. Nuwayhid ZB, Aronoff DM, Mulla ZD. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007;17:878-81.

30. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-5.

31. Schurr M, Engelhardt S, Helgerson R. Limb salvage for streptococcal gangrene of the extremity. Am J Surg 1998;175:213-7.

32. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007;44:705-10.

33. Brogan TV, Nizet V, Waldhausen JHT, Rubens CE, Clarke WR. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995;14:588-94.

34. Outbreak of invasive group A streptococcus associated with varicella in a childcare center — Boston, Massachusetts, 1997. MMWR Morb Mortal Wkly Rep 1997;46:944-8.

35. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000;105:E60.

36. Zakikhany K, Degail MA, Lamagni T, et al. Increase in invasive *Streptococcus pyogenes* and *Streptococcus pneumoniae* infections in England, December 2010 to January 2011. Euro Surveill 2011;16:19785.

37. Zachariadou L, Stathi A, Tassios PT, Pangalis A, Legakis NJ, Papaparaskevas J. Differences in the epidemiology between paediatric and adult invasive *Streptococcus pyogenes* infections. Epidemiol Infect 2014;142:512-9.

38. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924;9:317-64.

39. Stevens DL. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995;21:977-80.

40. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003;82:225-35.

41. Lesko SM. The safety of ibuprofen

suspension in children. Int J Clin Pract Suppl 2003;135:50-3.

42. Lamagni TL, Neal S, Keshishian C, et al. Severe *Streptococcus pyogenes* infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008;14:202-9.

43. Dubos F, Hue V, Grandbastien B, Catteau B, Martinot A. Bacterial skin infections in children hospitalized with varicella: a possible negative impact of non-steroidal anti-inflammatory drugs? Acta Derm Venereol 2008;88:26-30.

44. Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol 2008; 65:203-9.

45. Leroy S, Marc E, Bavoux F, et al. Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig 2010;30:179-85.

46. Das DK, Baker MG, Venugopal K. Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 2012;12:348.

47. Hamilton SM, Bayer CR, Stevens DL, Bryant AE. Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis. J Infect Dis 2014;209:1429-35.

48. Weng TC, Chen CC, Toh HS, Tang HJ. Ibuprofen worsens *Streptococcus pyogenes* soft tissue infections in mice. J Microbiol Immunol Infect 2011;44:418-23.

49. Hamilton SM, Bayer CR, Stevens DL, Lieber RL, Bryant AE. Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J Infect Dis 2008;198:1692-8.

50. Stevens DL, Laposky LL, McDonald P, Harris I. Spontaneous gas gangrene at a site of remote injury — localization due to circulating antitoxin. West J Med 1988; 148:204-5.

51. Stevens DL. Clostridial myonecrosis and other clostridial diseases. In: Bennett JC, Plum F, eds. Cecil textbook of medicine. 20th ed. Philadelphia: W.B. Saunders, 1996:2090-3.

52. Fleming A. On the bacteriology of septic wounds. Lancet 1915;186:638-43.

53. MacLennan JD. The histotoxic clostridial infections of man. Bacteriol Rev 1962;26:177-276.

54. Stewart JC. Anaerobic cellulitis. J Am Med Assoc 1905;45:528-35.

55. Qvist G. Anaerobic cellulitis and gas gangrene. Br Med J 1941;2:217-21.

56. Bodey GP, Rodriguez S, Fainstein V, Elting LS. Clostridial bacteremia in cancer patients: a 12-year experience. Cancer 1991;67:1928-42.

57. Stevens DL, Musher DM, Watson DA, et al. Spontaneous, nontraumatic gangrene due to *Clostridium septicum*. Rev Infect Dis 1990;12:286-96.

58. Aldape MJ, Bryant AE, Stevens DL. *Clostridium sordellii* infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006;43:1436-46.

59. Alayed KA, Tan C, Daneman N. Red flags for necrotizing fasciitis: a case control study. Int J Infect Dis 2015;36:15-20.

60. Carbonetti F, Cremona A, Carusi V, et al. The role of contrast enhanced computed tomography in the diagnosis of necrotizing fasciitis and comparison with the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC). Radiol Med 2016;121:106-21.

61. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis — the use of frozen-section biopsy. N Engl J Med 1984;310:1689-93.

62. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 1997;90: 1065-8.

63. Chelsom J, Halstensen A, Haga T, Høiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994;344:1111-5.

64. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg 2000; 191:227-31.

65. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32:1535-41.

66. Bechar J, Sepehripour S, Hardwicke J, Filobbos G. Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score for the assessment of early necrotising fasciitis: a systematic review of the literature. Ann R Coll Surg Engl 2017;99:341-6.

67. Burner E, Henderson SO, Burke G, Nakashioya J, Hoffman JR. Inadequate sensitivity of laboratory risk indicator to rule out necrotizing fasciitis in the emergency department. West J Emerg Med 2016;17:333-6.

68. Holland MJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care 2009;37:588-92.

69. Putnam LR, Richards MK, Sandvall BK, Hopper RA, Waldhausen JH, Harting MT. Laboratory evaluation for pediatric patients with suspected necrotizing soft tissue infections: a case-control study. J Pediatr Surg 2016;51:1022-5.

70. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10-e52.

71. Bandyopadhyay D, Jacobs JV, Panchabhai TS. What's new in emergencies, trauma and shock? The tortuous path in the management of necrotizing fasciitis: is early surgical intervention critical? J Emerg Trauma Shock 2016;9:1-2.

72. Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg 2014;51:344-62.

73. Crew JR, Varilla R, Allandale Rocas T III, Abdul Rani S, Debabov D. Treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive NeutroPhase irrigation under the foam. Wounds 2013;25:272-7.

74. Baharestani MM. Negative pressure wound therapy in the adjunctive management of necrotizing fasciitis: examining clinical outcomes. Ostomy Wound Manage 2008;54:44-50.

75. Lee JY, Jung H, Kwon H, Jung SN. Extended negative pressure wound therapy-assisted dermatotraction for the closure of large open fasciotomy wounds in necrotizing fasciitis patients. World J Emerg Surg 2014;9:29.

76. Freischlag JA, Ajalat G, Busuttil RW. Treatment of necrotizing soft tissue infections: the need for a new approach. Am J Surg 1985;149:751-5.

77. Bucca K, Spencer R, Orford N, Cattigan C, Athan E, McDonald A. Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ J Surg 2013;83:365-70.

78. Hadeed GJ, Smith J, O'Keeffe T, et al. Early surgical intervention and its impact on patients presenting with necrotizing soft tissue infections: a single academic center experience. J Emerg Trauma Shock 2016;9:22-7.

79. Hawser S, Hoban DJ, Badal RE, et al. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011. J Chemother 2015;27:67-73.

80. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017;61(4): e02349-16.

81. Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents 2017;49:770-3.

82. DeMuri GP, Sterkel AK, Kubica PA, Duster MN, Reed KD, Wald ER. Macrolide and clindamycin resistance in group A streptococci isolated from children with pharyngitis. Pediatr Infect Dis J 2017;36: 342-4.

83. Peng XM, Yang P, Liu S, et al. The genetic features of drug resistance to group A streptococcus and macrolides antibiotics among pediatric patients in Beijing 2012. Zhonghua Yu Fang Yi Xue Za Zhi 2013;47:1040-4. (In Chinese.)

84. Lewis JS II, Lepak AJ, Thompson GR III, et al. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob Agents Chemother 2014; 58:1327-31.

85. Bryant AE, Aldape MJ, Bayer CR, McIndoo E, Stevens DL. Efficacy of tedizolid in experimental myonecrosis caused by erythromycin/clindamycin-sensitive and -resistant group A streptococcus. In: Proceedings and Abstracts of 2016 IDWeek, New Orleans, October 26–30, 2016.

86. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to *Clostridium perfringens*. J Infect Dis 1987;155:220-8.

87. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-77.

88. Stevens DL, Shelly MP, Stiller R, Villasenor-S A, Bryant AE. Acute reversible cardiomyopathy in patients with streptococcal toxic shock syndrome. In: Proceedings of the XVIIth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Athens, June 22–26, 2008.

89. Wang C, Schwaitzberg S, Berliner E, Zarin DA, Lau J. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003;138:272-9.

90. Jallali N, Withey S, Butler PE. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005;189:462-6.

91. Willy C, Rieger H, Vogt D. Hyperbaric oxygen therapy for necrotizing soft tissue infections: contra. Chirurg 2012;83:960-72. (In German.)

92. Shaw JJ, Psoinos C, Emhoff TA, Shah SA, Santry HP. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt) 2014;15: 328-35.

93. Stevens DL, Bryant AE, Adams K, Mader JT. Evaluation of hyperbaric oxygen therapy for treatment of experimental *Clostridium perfringens* infection. Clin Infect Dis 1993;17:231-7.

94. Hansen MB, Simonsen U, Garred P, Hyldegaard O. Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation — the protocol of the prospective cohort BIONEC study. BMJ Open 2015;5(5):e006995.

95. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. Clin Infect Dis 1999;28:800-7.

96. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.

97. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009;49:1369-76.

98. Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014;59:851-7.

99. Kadri SS, Swihart BJ, Bonne SL, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis 2017;64:877-85.

100. Bulger EM, Maier RV, Sperry J, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg 2014;149:528-36.

Copyright © 2017 Massachusetts Medical Society.

IMAGES IN CLINICAL MEDICINE

The *Journal* welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the *Journal*'s website at NEJM.org. At the discretion of the editor, images that are accepted for publication may appear in the print version of the *Journal*, the electronic version, or both.